Volume 17, Number 5—May 2011
Research
Plasmodium knowlesi Malaria in Children
Table 2
Species and treatment regimen | No. (%) patients | Days until negative smear† |
---|---|---|
P. knowlesi, n = 16 | ||
3 days CQ/PQ | 13 (81) | 2 (2–3, 1–5) |
Oral Q | 2 (13) | 2, 2 |
IV Q | 1 (6) | 2 |
All |
2 (2–3, 1–5) |
|
P. falciparum, n = 14 | ||
3 days CQ/PQ → oral Q | 2 (14) | 5, 5 |
Oral Q → AL | 1 (7) | 3 |
SP/PQ → AM | 1 (7) | 8 |
SP/PQ | 2 (14) | 1, 2 |
SP/PQ → CQ/Q → AL | 1 (7) | 3 |
SP/PQ → CQ/IV Q → AL | 1 (7) | 5 |
SP/PQ → CQ/IV Q → oral Q | 1 (7) | 3 |
SP/PQ → oral Q → IV Q → oral Q | 1 (7) | 16 |
IV Q → oral Q | 2 (14) | 1, 10 |
IV Q → oral Q/PQ | 1 (7) | 11 |
Oral Q/PQ → AM | 1 (7) | 10 |
All | 5 (3–10, 1–16)‡ |
*IQR, interquartile range; CQ, chloroquine; PQ, primaquine; Q, quinine; IV, intravenous; AL, artemether/lumefantrine; SP, sulfamethoxazole/pyrimethamine; AM, artesunate/mefloquine.
†Values are mean (IQR, range) by category or days by patient.
‡p value = 0.009 for days until negative smear for P. falciparum vs. P. knowlesi.
Page created: August 09, 2011
Page updated: August 09, 2011
Page reviewed: August 09, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.